Recruiting
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
NCT07763210· Phase 2· Vanderbilt-Ingram Cancer Center· Source
Contact: Vanderbilt-Ingram Service Services for Timely Access
Recruiting
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
NCT07441681· Phase 3· NRG Oncology· Source
Contact: Jennifer H. Choe (principal investigator)
Recruiting
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
NCT07673367· Phase 2· Vanderbilt-Ingram Cancer Center· Source
Contact: Vanderbilt-Ingram Service Services for Timely Access
Recruiting
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
NCT07003295· Phase 2· National Cancer Institute (NCI)· Source
Contact: Shakthi Bhaskar (principal investigator)
Recruiting
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
NCT07195734· Phase 2· National Cancer Institute (NCI)· Source
Contact: Jennifer H. Choe (principal investigator)
Recruiting
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
NCT07068074· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Contact: Cameron E. Schlegel (principal investigator)
Recruiting
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· Phase 3· National Cancer Institute (NCI)· Source
Contact: Alaina J. Brown (principal investigator)
Recruiting
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NCT06686771· Phase 3· Canadian Cancer Trials Group· Source
Contact: Evan C. Osmundson (principal investigator)
Recruiting
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT07216443· Phase 2· Orca Biosystems, Inc.· Source
Contact: Bhagirathbhai Dholaria
Recruiting
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
NCT07001748· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source
Contact: Deepa Magge (principal investigator)
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT07097142· Phase 3· NRG Oncology· Source
Contact: Austin N. Kirschner (principal investigator)
Recruiting
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
NCT07016399· Phase 2· Vandana Abramson· Source
Contact: Vandana G. Abramson
Recruiting
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
NCT06661915· Phase 2· National Cancer Institute (NCI)· Source
Contact: Ashwin Kishtagari (principal investigator)
Active, not recruiting
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
NCT06732401· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
NCT06860594· Phase 1· National Cancer Institute (NCI)· Source
Contact: Alexander C. Mohler (principal investigator)
Recruiting
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
NCT06696768· Phase 1· National Cancer Institute (NCI)· Source
Contact: Kristen K. Ciombor (principal investigator)
Recruiting
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06317662· Phase 2· National Cancer Institute (NCI)· Source
Contact: Brianna N. Smith (principal investigator)
Recruiting
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157· Phase 2· National Cancer Institute (NCI)· Source
Contact: Brianna N. Smith (principal investigator)
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· Phase 3· Canadian Cancer Trials Group· Source
Contact: Kerry R. Schaffer (principal investigator)
Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330· Phase 3· Children's Oncology Group· Source
Contact: Daniel J. Benedetti (principal investigator)
Recruiting
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
NCT06647953· Phase 3· Children's Oncology Group· Source
Contact: Daniel J. Benedetti (principal investigator)
Recruiting
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Brian I. Rini (principal investigator)
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· Phase 3· NRG Oncology· Source
Contact: Alaina J. Brown (principal investigator)
Recruiting
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962· Phase 3· Children's Oncology Group· Source
Contact: Elizabeth J. Davis (principal investigator)
Recruiting
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
NCT06475989· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Contact: Jennifer H. Choe (principal investigator)
Active, not recruiting
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· Phase 3· NRG Oncology· Source
Active, not recruiting
Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules
NCT06638398· Vanderbilt-Ingram Cancer Center· Source
Recruiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
NCT06368817· Phase 2· Children's Oncology Group· Source
Contact: Adam J. Esbenshade (principal investigator)
Active, not recruiting
Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial
NCT06593106· Vanderbilt-Ingram Cancer Center· Source
Recruiting
EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing
NCT06105801· Phase 4· Vanderbilt-Ingram Cancer Center· Source
Contact: Vanderbilt-Ingram Service Services for Timely Access
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· Phase 3· National Cancer Institute (NCI)· Source
Contact: Elizabeth J. Davis (principal investigator)
Recruiting
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
NCT06399640· Phase 1· Vanderbilt-Ingram Cancer Center· Source
Contact: Vanderbilt-Ingram Service Services for Timely Access
Active, not recruiting
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
NCT06169215· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
NCT05711667· Phase 3· Children's Oncology Group· Source
Contact: Carrie L. Kitko (principal investigator)
Recruiting
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485· Phase 3· Canadian Cancer Trials Group· Source
Contact: Cathy Eng (principal investigator)
Recruiting
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
NCT06064097· Phase 2· National Cancer Institute (NCI)· Source
Contact: Scott C. Borinstein (principal investigator)
Recruiting
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
NCT06016855· Phase 4· Vanderbilt-Ingram Cancer Center· Source
Contact: Vanderbilt-Ingram Service for Timely Access
Recruiting
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
NCT06110572· Phase 1/2· Vanderbilt-Ingram Cancer Center· Source
Contact: Vanderbilt-Ingram Service for Timely Access
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296· Phase 3· National Cancer Institute (NCI)· Source
Contact: Daniel J. Benedetti (principal investigator)
Recruiting
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT05863195· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Contact: Chandrasekhar Padmanabhan (principal investigator)
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· Phase 2/3· National Cancer Institute (NCI)· Source
Contact: Kerry R. Schaffer (principal investigator)
Active, not recruiting
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
NCT05761171· Phase 2· Children's Oncology Group· Source
Active, not recruiting
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT05554367· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
NCT05702645· Children's Oncology Group· Source
Contact: Debra L. Friedman (principal investigator)
Recruiting
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
NCT05803382· Phase 1· National Cancer Institute (NCI)· Source
Contact: Thatcher R. Heumann (principal investigator)
Active, not recruiting
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
NCT05836571· Phase 2· National Cancer Institute LAO· Source
Recruiting
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
NCT05673148· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Chandrasekhar Padmanabhan (principal investigator)
Recruiting
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
NCT05770531· Phase 2· Vanderbilt-Ingram Cancer Center· Source
Contact: Vanderbilt-Ingram Service for Timely Access
Recruiting
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer
NCT05945875· Phase 1· Vanderbilt-Ingram Cancer Center· Source
Contact: Vanderbilt-Ingram Service Services for Timely Access
Recruiting
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT05693766· Phase 2· Sonya Reid· Source
Contact: Vanderbilt-Ingram Service for Timely Access
Showing 50 of 241.